Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab

The relatively low toxicity profile of nab-paclitaxel plus carboplatin and its feasibility as an adjuvant administration was reported previously. This study aimed to evaluate the survival efficacy for completely resected patients with stage IB, II, and IIIA nonsmall cell lung cancer (NSCLC). Twenty-...

Descripción completa

Detalles Bibliográficos
Autores principales: Marushima, Hideki, Kimura, Hiroyuki, Miyazawa, Tomoyuki, Sakai, Hiroki, Furuya, Naoki, Koji, Kojima, Nakamura, Haruhiko, Saji, Hisashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964868/
https://www.ncbi.nlm.nih.gov/pubmed/31725045
http://dx.doi.org/10.1097/CAD.0000000000000857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964868/
https://www.ncbi.nlm.nih.gov/pubmed/31725045
http://dx.doi.org/10.1097/CAD.0000000000000857

Ejemplares similares